Mouwasat Medical Services Company (TADAWUL: 4002)
Saudi Arabia
· Delayed Price · Currency is SAR 87.60
-0.60 (-0.68%)
Dec 19, 2024, 3:17 PM AST
Mouwasat Medical Services Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2,897 | 2,706 | 2,334 | 2,144 | 2,045 | 1,857 | Upgrade
|
| Revenue Growth (YoY) | 11.74% | 15.91% | 8.86% | 4.85% | 10.11% | 10.74% | Upgrade
|
| Cost of Revenue | 1,551 | 1,411 | 1,249 | 1,163 | 1,096 | 1,038 | Upgrade
|
| Gross Profit | 1,346 | 1,295 | 1,085 | 981.46 | 948.58 | 819.64 | Upgrade
|
| Selling, General & Admin | 455.68 | 429.25 | 400.78 | 359.53 | 370.75 | 349.15 | Upgrade
|
| Other Operating Expenses | -9.73 | -8.38 | -6.73 | - | - | - | Upgrade
|
| Operating Expenses | 603.6 | 538.12 | 412.32 | 359.53 | 370.75 | 349.15 | Upgrade
|
| Operating Income | 742.61 | 756.56 | 672.46 | 621.93 | 577.84 | 470.49 | Upgrade
|
| Interest Expense | -35.48 | -46.46 | -22.88 | -8.2 | -14.04 | -20.16 | Upgrade
|
| Interest & Investment Income | 9.4 | 6.48 | 0.58 | 0.32 | 1.4 | 1.97 | Upgrade
|
| Earnings From Equity Investments | 5.46 | 10.21 | 9.88 | 10.45 | 4.16 | 3.62 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 7.71 | 7.12 | 5.89 | Upgrade
|
| EBT Excluding Unusual Items | 721.98 | 726.79 | 660.03 | 632.21 | 576.47 | 461.82 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.29 | 0.29 | 0.24 | -0.02 | 0.4 | 0.41 | Upgrade
|
| Pretax Income | 722.27 | 727.09 | 660.27 | 632.2 | 576.87 | 462.23 | Upgrade
|
| Income Tax Expense | 39.82 | 38.7 | 27.58 | 21.73 | 15.24 | 13.47 | Upgrade
|
| Earnings From Continuing Operations | 682.45 | 688.39 | 632.69 | 610.46 | 561.63 | 448.76 | Upgrade
|
| Minority Interest in Earnings | -24.36 | -30.7 | -33.38 | -32.3 | -33.47 | -27.73 | Upgrade
|
| Net Income | 658.09 | 657.69 | 599.31 | 578.16 | 528.16 | 421.03 | Upgrade
|
| Net Income to Common | 658.09 | 657.69 | 599.31 | 578.16 | 528.16 | 421.03 | Upgrade
|
| Net Income Growth | -0.13% | 9.74% | 3.66% | 9.47% | 25.44% | 16.89% | Upgrade
|
| Shares Outstanding (Basic) | 200 | 200 | 200 | 200 | 200 | 200 | Upgrade
|
| Shares Outstanding (Diluted) | 200 | 200 | 200 | 200 | 200 | 200 | Upgrade
|
| EPS (Basic) | 3.29 | 3.29 | 3.00 | 2.89 | 2.64 | 2.11 | Upgrade
|
| EPS (Diluted) | 3.29 | 3.29 | 3.00 | 2.89 | 2.64 | 2.11 | Upgrade
|
| EPS Growth | -0.13% | 9.74% | 3.66% | 9.47% | 25.44% | 16.89% | Upgrade
|
| Free Cash Flow | 548.06 | 536.75 | 414.52 | 355.9 | 250.81 | 376.04 | Upgrade
|
| Free Cash Flow Per Share | 2.74 | 2.68 | 2.07 | 1.78 | 1.25 | 1.88 | Upgrade
|
| Dividend Per Share | 1.750 | 1.750 | 1.500 | 1.375 | 1.250 | 1.000 | Upgrade
|
| Dividend Growth | 16.67% | 16.67% | 9.09% | 10.00% | 25.00% | 14.29% | Upgrade
|
| Gross Margin | 46.47% | 47.85% | 46.48% | 45.77% | 46.38% | 44.13% | Upgrade
|
| Operating Margin | 25.63% | 27.96% | 28.81% | 29.01% | 28.26% | 25.33% | Upgrade
|
| Profit Margin | 22.72% | 24.31% | 25.68% | 26.96% | 25.83% | 22.67% | Upgrade
|
| Free Cash Flow Margin | 18.92% | 19.84% | 17.76% | 16.60% | 12.26% | 20.25% | Upgrade
|
| EBITDA | 972.24 | 974.55 | 855.25 | 773.9 | 720.79 | 610.31 | Upgrade
|
| EBITDA Margin | 33.56% | 36.02% | 36.64% | 36.09% | 35.25% | 32.86% | Upgrade
|
| D&A For EBITDA | 229.63 | 217.99 | 182.79 | 151.97 | 142.96 | 139.82 | Upgrade
|
| EBIT | 742.61 | 756.56 | 672.46 | 621.93 | 577.84 | 470.49 | Upgrade
|
| EBIT Margin | 25.63% | 27.96% | 28.81% | 29.01% | 28.26% | 25.33% | Upgrade
|
| Effective Tax Rate | 5.51% | 5.32% | 4.18% | 3.44% | 2.64% | 2.91% | Upgrade
|
| Revenue as Reported | 2,897 | 2,706 | 2,334 | 2,144 | 2,045 | 1,857 | Upgrade
|
| Advertising Expenses | - | 35.17 | 28.26 | 26.82 | 28.15 | 33.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.